A carregar...
Androgen Receptor Variant–Driven Prostate Cancer II: Advances in Laboratory Investigations
BACKGROUND: The androgen receptor (AR) is a key prostate cancer drug target. Suppression of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing AR-directed therapies. AR-targeting agents impart therapeutic benefit, but lead to AR aberrations that underlie dise...
Na minha lista:
| Publicado no: | Prostate Cancer Prostatic Dis |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7725416/ https://ncbi.nlm.nih.gov/pubmed/32139878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-020-0217-3 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|